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In the recent years, the cost for both genotyping and sequencing has been decreas-
ing, making it possible to increase the number of individuals to be included in the
genetics research. Large sample sizes together with detailed phenotypic and med-
ical information have allowed researchers to address the role of genetic basis of
several common complex diseases. Even though a lot is yet to be discovered about
the genetic architecture of common complex diseases, scientists are already work-
ing on translating the current knowledge into advancements of everyday clinical
setting.
One of the most studied (and also most common) source of genetic variation is
single nucleotide polymorphisms (SNP). Even though SNPs explain only a frac-
tion of the heritability of common complex diseases, their incremental value on
top of classical risk factors has been shown to exist for many common complex
diseases such as type 2 diabetes, coronary artery disease, breast cancer, etc. As
each SNP usually has a small effect on a common complex disease, one needs to
take into account the effects of many SNPs simultaneously to effectively estimate
the genetic predisposition of a person. One option to do that is to use genetic risk
scores (GRS, also referred to as "polygenic risk score").
GRS is essentially a sum of weighted effect allele counts of SNPs. However,
their computation involves methodological challenges, as an optimal decision on
the choice of SNPs and their weights needs to be made. The most popular choice
used to be to include only a small number of SNPs, which association with a trait
had been confirmed in several large studies. Later on more sophisticated methods
have arisen since then.
It current thesis I first give an introduction to biological background related
to genome-wide association studies (GWAS) and then describe in detail both the
methodological and technical side of GWAS and meta-analysis. In the second part
I introduce the basics of genetic risk scores and then focus on the new method
which we have developed to improve genetic risk scores, called as the doubly-
weighted GRS. I demonstrate its superiority compared to single-weighting with
both simulations and with real data, using type 2 diabetes as an example (Ref I).
In Ref II, I explain the idea of metaGRS by M. Inouye and colleagues and imple-
ment it to find the best predicting GRS for breast cancer. I also discuss the issue
of non-uniqueness of the genetic risk score and its impact on genetic feedback.
In Ref III, the effect of population admixture on genetic risk scores is assessed
and the transferability of scores across populations is debated. Finally, in Ref IV,
I focus on the aspects of validating and comparing non-genetic risk scores for
cardiovascular diseases and cardiovascular death based on classical risk factors in
Estonian Biobank. The goal was to assess whether internationally acknowledged
scores are applicable in the Estonian population in the original form. I also com-
pare the prevention guidelines in regards to statin recommendations to assess the
overall cardiovascular disease risk levels in the Estonian Biobank.
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1. BACKGROUND OF STATISTICAL ANALYSIS IN
GENETICS
1.1. Introduction
The field of genetics has tight connections to medicine, as one of the current goals
of research in genetics is to reveal the underlying biological mechanisms for dis-
eases and traits. Screening for disorders with known genetic background is often
already implemented in clinical practice. For example, prenatal genetic screening
helps to identify babies with severe genetic disorders such as Down or Edwards
syndrome and sickle cell anemia. There are inherited disorders such as famil-
ial hypercholesterolemia caused by mutations in certain genes. Screening these
genes allows to identify disease causing mutations and use preventative measures
for affected individuals[1]. However, exposing the underlying genetic structure
for common complex diseases has remained a challenge.
In 2008, several leading scientists from the field of human genetics[2] stated
that the ultimate goal – to fully describe the genetic architecture of common com-
plex diseases and to translate the finding into clinical practice has remained un-
solved despite of the efforts. Yet it was also said that the identification of the vari-
ants, genes and pathways which are involved in certain diseases provides routes
to new therapies, advanced diagnosis and enchanted disease prevention[3]. Now,
ten years later, various authors are starting to express hope that already known
genetic information could be successfully implemented in prevention of at least
some common complex diseases[4–6].
1.2. DNA
This chapter is written based on materials of National Human Genome Research
Institute[7] and the book by prof. A. Heinaru[8].
DNA (deoxyribonucleic acid) is the hereditary material present mostly in the cell’s
nucleus. DNA could be seen as a code built with four letters (nitrogen bases): ade-
nine (A), guanine (G), cytosine (C) and thymine (T). DNA bases pair up with each
other (adenine pairs with thymine and cytosine pairs with guanine), forming units
called base pairs. Each base is also attached to a sugar molecule and a phosphate
molecule. These three components (base, sugar and phosphate molecule) together
are called a nucleotide. Nucleotides form a strand of DNA and two strands wound
around each other form a spiral called a double helix. Human DNA consists of
approximately 3 billion bases and that entire sequence is called a genome.
DNA molecule in the nucleus of each cell is packaged into thread-like structure
called chromosomes. Normally, humans have 23 pairs of chromosomes, twenty-
two pairs are called autosomes and the 23rd pair - the sex chromosomes- differs
between males and females. Females have two copies of X chromosome and
males have one X and one Y chromosome.
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1.3. Types of genomic variation
Genetic variations can be present in many forms in human genome. In the broad-
est way, genetic variants can be divided into two different classes: single nu-
cleotide variants and structural variants (see Figure 1). Single nucleotide variant is
a variable position in human genome where the single nucleotide is substituted by
another[9]. Most of the single nucleotide variants are di-allelic, meaning that only
two alternative nucleotides (two alleles) can be detected in the specific position.
The allele with smaller frequency in the population is referred to as a minor allele.
Single nucleotide variants are classified to either as common or rare, depending
on the frequency of minor allele (MAF) in the human population. Common single
nucleotide variants have minor allele frequency of at least 1% (this is somewhat
an arbitrary cut-off) in the population and they are often referred as single nu-
cleotide polymorphisms (SNPs)[9–11]. Structural variants include insertions and
deletions (indels), tandem repeats, copy number variations and other chromoso-
mal rearrangements[9, 12].
Figure 1. Different classes of human genetic variants. Insertion-deletion variant is oc-
curring when a sequence of base pairs is present on some genome and missing in others.
Inversion variant is present when an order of base pair sequence is reversed in a chro-
mosome. Tandem repeat is a variant where a short sequence of base pairs is repeated.
Adapted from[9].
According to the 1000 Genomes project, more than 88 million genetic variants
were identified in the humans, approximately 84 million of them single nucleotide
variants. Therefore, single nucleotide variants are the most frequent type of vari-
ation in the human genome. Most of them are rare, only 20 million are present
with MAF >0.5% and 8 million with MAF 5% or more[13]. Due to abundance of
single nucleotide variants and the fact that they are widespread across the entire
genome makes them useful variables to study genomic alterations[10].
Single nucleotide variants are not always universal among major populations.
Some are present in only one major population such as Europeans, but many of
them are shared across all populations. Individuals from African ancestry popu-
lation are currently believed to be most genetically diverse[13, 14].
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The location of the single nucleotide variant might have several consequences
at the phenotypic level. If the single nucleotide variant is in the coding area of
the gene, it might alter the function of the encoded protein. However, most of
the single nucleotide variants are located in the non-coding regions[15]. Recent
research has been focusing on SNPs appearing in the non-coding, but regulatory
regions (regions that do not code for proteins, but control the expression of coding
regions) in hope for better understanding of the mechanism underlying complex
traits[16, 17].
1.4. Haplotype and linkage disequilibrium
First, both terms - haplotype and linkage disequilibrium - have several defini-
tions and only some of them are described here. Haplotype is a set of alleles
in the same chromosome inherited together from a single parent[8]. They tend
to be highly conserved areas which remain the same during many generations of
reproduction[18]. When alleles are non-randomly inherited, then they are said to
be in linkage disequilibrium (LD)[19]. The levels of LD tend to be higher when
alleles are physically close to each other in the chromosome. There are several
different measures to characterise LD, one of them being square of Pearson cor-
relation.
When a set of SNPs are in high LD, then not all of them are usually needed to
define haplotypes. The subset of SNPs representing a larger set of SNPs due to LD
are called tag SNPs[20]. There are numerous methods to select tag SNPs, one of
them is maximising the minimum correlation between non-tag and tag SNPs[20].
1.5. Genotyping, whole genome sequencing and imputation
A comprehensive method to analyse the genome is whole genome sequencing
(WGS), which provides base-by-base view of the genome. This method (cur-
rently considered a “golden standard” for genetic testing[21]) allows capturing
more complicated structural variants and de novo mutations which cannot be de-
tected with genotyping array without beforehand knowledge of their existence and
location.
Whole genome genotyping is a laboratory based approach, were SNP arrays
allow the identification of hundreds of thousands of single nucleotide polymor-
phisms located all over the genome. There are several approaches how to genotype[15,
22]. The two major SNP genotyping array providers currently are Affymetrix[23]
and Illumina[24].
The huge number of SNPs creates a problem while genotyping: it is not cost
effective to genotype all of them[12]. Therefore, only a subset of tag SNPs are se-
lected for genotyping and the ungenotyped SNPs in the genome are later imputed
- their genotypes are predicted based on LD between tagged and untagged SNPs.
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The idea of imputation is to predict the unobserved SNPs in a genotyped sam-
ple using a reference panel (usually whole-genome sequencing data from a sim-
ilar population to the study sample). It requires that there is a sufficient overlap
of genotyped SNPs in both study sample and the reference panel. Both reference
data and genotype data must be phased (two independent haplotypes etc.)
Figure 2. Explanatory drawing of imputation. Reference panel is usually constructed
from a whole genome sequencing data with all positions known. Inference panel results
from genotyping, where only tag SNPs are known, and the rest of them needs to be im-
puted. Adapted from[25].
Genotyping platforms often provide genotypic information, but no information
about haplotypes. Even though haplotypes can be determined through molecu-
lar methods, it is often not done due to its cost and time consumption[26]. So
haplotypes are determined from genotypic data using statistical methods. After
constructing haplotypes and estimating their frequencies, imputation can be done,
often based on hidden Markov models[25]. As a result of imputation, posterior
probability of each possible genotype of a missing SNP for each individual is
estimated, given the observed data.
A reference panel can be population specific (for example Estonian whole
genome sequencing data) or mixture of different populations, such as publicly
available 1000 Genome Project[13] or international HapMap resources[27]. The
choice of reference panel is important as differences in LD patterns between refer-
ence study and imputed study reduces the accuracy of imputation[28]. Imputation
is necessary to boost the power of genome-wide association studies and allow
meta-analysing summary results from cohorts genotyped with different genotyp-
ing platforms[2, 28].
There are several different software solutions available for imputation, Esto-
nian Biobank has been using IMPUTE2[25] and BEAGLE[29]. Both of those
tools also provide measures to estimate imputation accuracy (as imputation is
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done with uncertainty), which allows to filtering out and excluding low quality
SNPs from the analysis. As most of my research uses imputed data filtered for
imputation quality, the imputation quality (often called INFO score) is defined
followingly[28].
It is assumed that for each SNP, three possible genotypes exist (for the sake of
this example, lets say aa, Aa and AA). One allele is chosen to be counted ("coded
allele", in this example allele "A") and the genotypes are presented as allele "A"
counts, either 0, 1 or 2. It is usually assumed, that SNPs follow Hardy-Weinberg
equilibrium, which states that in the absence of disturbing events the allele and
genotype frequencies in a population will remain unchanged over time[30]. This
means, that for one SNP with two possible alleles "A" with frequency pA and "a"
with frequency pa, the genotype "aa" frequency can be calculated as p2a, genotype
Aa frequency as 2pa pA and genotype "AA" frequency as p2A.
Let the genotype of the ith individual (i = 1, ...,N) at the jth SNP be denoted
as Gi j ∈ {0,1,2}. Let the set of haplotypes be denoted with H and the set of
genotyped tag SNPs with G. Let the pi jk = P(Gi j = k|G,H) be the probability
(obtained from imputation) of ith individual having the kth genotype for jth SNP.




pi jk = 1. The expected coded allele dosage at the ith indi-
vidual for jth SNP is defined as ei j = pi j1 + 2pi j2. We also define the expected
squared allele dosage fi j as fi j = pi j1 +4pi j2. The unknown population coded al-






The imputation INFO measure in IMPUTE for the jth SNP is based on a ratio
of sample mean variance of the imputed genotypes and expected variance of jth





i=1( fi j− e2i j)
2Nθ̂ j(1− θ̂ j)
when θ̂ j ∈ (0,1);
1 when θ̂ j ∈ {0,1}.
(1.1)
Common thresholds for INFO score vary from 0.4 for genome-wide association
studies[31] to 0.7-0.8 for polygenic risk score construction studies[32].
The final choice of which array to use depends on many factors such as the re-
search objectives, cost, array delivery schedules and available capacity of genotyping[2].
But even though the cost of sequencing has decreased dramatically over the past
few years (being now 1000-2000 US dollars per genome[14]), majority of the
genome-wide association studies for common complex traits/diseases (such as
obesity, type 2 diabetes, breast cancer or coronary artery disease, etc) are still
based on genotyped data together with imputation[4, 33–36].
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1.6. Genome-wide association study
The idea of a genome-wide association study (GWAS) is to look for associations
between a phenotype variable Y and each of the available SNPs across the entire
genome. In the classical GWAS, it is assumed that individuals are unrelated. Due
to the fact that the number of individuals n is often smaller than the number of
SNPs, then each SNP is separately modelled to test for association in GWAS.
Suppose there are m SNPs X1, . . . ,Xm we want to analyse. Let there be l covariates
denoted as Z j, j = 1, ..., l. The model for the ith SNP can be written in a form of
generalized linear model with a link function g(·)




γ jZ j (1.2)
Depending on how the SNP is coded, different genetic models can be investigated[37].
Using the arbitrary alleles "A" and "a" for a SNP like in the previous paragraph,
genetic models can be additive - SNP genotype coded as "aa":0,"Aa":1,"AA":2;
recessive - genotype coded as "AA":0,"Aa":0,"aa":1 or dominant - genotype coded
as "aa":0,"Aa":1,"AA":1. Often additive models are applied in complex disease’s
studies.
If Y is a continuous random variable and linear relationship between Y and
each SNP is assumed to hold, then identity link is appropriate. If Y is binary, then






can be applied. Often - but not always - the covariates Z j which are accounted for
while modelling the SNP-phenotype association are age at recruitment, sex and a
number of principal components to account for possible population stratification.
The ith SNP is said to be genome-wide significant if the p-value from testing
the null hypothesis that βi = 0 is ≤ 5 · 10−8 as it has been estimated that there
are approximately 1 million independent common SNPs in the genome[38] and
Bonferroni corrected significance threshold is 5 ·10−8.
Several potential biases can occur in GWAS studies. There might be technical
issues like different genotyping platforms for cases and controls[39]. Another
major problem is the failure to properly account for population stratification or
cryptic relatedness[2, 40]. Latter problems can be addressed with mixed linear
models, however, their usage in practice until recent has been limited mainly due
to computational issues[40, 41].
1.7. Meta-analysis of GWAS
Meta-analysis attempts to combine the analysis results from several individual
studies to aggregate available information[42] and to provide pooled estimates.
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It tackles the common concern of genetic data privacy, as no sharing of individ-
ual level data is required. It also avoids combining phenotype and genotype data
together from several studies, which can be a harrowing job due to different dis-
ease coding systems and data formats. And finally, it allows for study-specific
covariate adjustment[43].
The most common approach to perform meta-analysis with studies from sim-
ilar ethnic background is fixed effect (FE) approach. FE approach assumes that
there is no heterogeneity with respect to the true effect size of a SNP across all
included studies[44].
To estimate the common underlying effect size by combining multiple ob-
served effect sizes θ1, . . . ,θn together from n independent studies, weighted mean








Under the assumption, that θi are asymptotically normally distributed with
the same mean, the maximum likelihood estimator will be obtained by choos-
ing wi = 1/(Var(θi))[45]. This resulting estimator is called the inverse variance-
weighted average effect size estimator. To test the null hypothesis that the com-
mon underlying effect is zero, z-statistic ZIVW =
θ√
Var(θ)
can be calculated and
p-value obtained as p = 2Φ(− | ZIVW |).
In GWAS setting, θi are effect estimates such as linear regressions coefficients
or log odds ratios denoted as β̂1, ..., β̂n for a SNP from n independent studies
and let σ̂21 , ..., σ̂2n be their estimated variances, respectively. For simplicity, the
estimated variances are often treated as known true variances[45, 46].
The inverse-variance-weighted (IVW) average effect size estimate for the com-




















Normally, meta-analysis is done for millions of SNPs. The output is one huge
file containing (but not limited to) information about SNP ID, its position in the
chromosome, chromosome, reference allele, alternative allele, alternative allele
frequency, sample size, inverse-variance weighted effect size estimator for an al-
ternative allele and its variance and p-value from testing the null hypothesis that
the effect size is zero. This information is essential of developing genetic risk
scores.
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Most of the GWA studies have been focusing on individuals with European an-
cestry. But in general, disease risk variants detected by GWASs seem to be shared
across diverse populations[47, 48]. Transethnic meta-analyses are becoming in-
creasingly popular to find population specific SNPs, increase the sample size of
the studies as well as replicate previously found associations. It has been observed
for type 2 diabetes for instance, that there is quite large directional consistency for
allelic effects among different populations[49]. However, several challenges exist
for transethnic studies. For instance, not all SNPs are polymorphic in all popu-
lations. Also, LD structures between SNPs as well as minor allele frequencies
of SNPs might vary across populations[50]. It is also possible, that interactions
between SNPs and environmental factors with different exposure levels between
ethnic groups exist[51].
Two most popular programs to perform meta-analysis with studies from simi-
lar ethnic group are GWAMA[52] and METAL[43]. For trans-ethnic meta-analysis,
various methods have been considered (for example, random effects meta-analysis,
MANTRA or MR-MEGA)[47, 53].
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2. GENETIC RISK SCORES
Over the years, genome-wide association studies have identified many SNPs as-
sociated with common complex diseases, however, most of them with relatively
small effect on disease, deeming most of them alone worthless in clinical risk pre-
diction. While searching for ways to make use of knowledge provided by GWAS,
an idea of combining the effects of many SNPs into one variable called genetic
risk score was presented. Genetic risk scores are nowadays one of the most re-
searched topics in statistical/medical genetics field as they play an important role
in explaining the genetic component of diseases’ liabilities. In this paragraph, both
the importance of genetic risk scores as well as different methods of composing
genetic risk scores are introduced.
2.1. Common complex disease
By common complex disease we consider a frequently occurring chronic disease
that has multifactorial aetiology, where both genetic susceptibility and environ-
mental risk factors (including, but not limited to lifestyle and other health con-
ditions) contribute[54]. Typical examples include coronary artery disease, type 2
diabetes, cancers, etc. Common complex diseases can affect the quality of life and
as they also tend to have serious complications, it is desirable both for individual
and health care system to prevent or postpone the onset of a disease as efficiently
as possible. Estimating susceptibility of an individual to disease is a vital step
in a clinical decision-making, especially as early disease detection and interven-
tion is crucial to improve human health. Currently, most of the clinically used
risk prediction tools are based on demographic and lifestyle variables such as age,
sex, ethnicity, body mass index, alcohol and tobacco consumptions[55]. Clinical
biomarkers and family history are also often incorporated[56, 57]. Even though
one could argue that genetic predisposition is the earliest measurable component
contributing to common complex disease, it is often missing from prediction tools.
There are several reasons for that. First, it was studied that adding GRS into risk
prediction tools already incorporating individual’s family history and other risk
factors would not improve the model[58], and therefore one could assume that
family history at least partially already accounts for individual’s genetic predispo-
sition. Now it has been shown for several diseases that accounting for both indi-
vidual’s family history (if known) and genetic predisposition via genetic risk score
results in the highest predictive ability[32, 59], proving them both as useful pre-
dictors. Second, the estimation of genetic risk was rather limited in the beginning
and therefore showed little incremental value for clinical prediction tools[60, 61].
With more sophisticated statistical methods to compute genetic risk scores, its use
in screening and prevention strategies has been encouraged[55, 62–64].
21
2.2. Heritability
Lets say there is a phenotype P which can be modelled in a simple case as the
sum of environmental (E) and genetic (G) effects: P = G+ E. Heritability is
defined as the ratio of the genetic variation to the phenotypic variation, ie H2 =
Var(G)
Var(P)
. Heritability estimates depend on several aspects, including the popula-
tion they were derived in and the disease they were derived for[65]. Heritabil-
ity is often estimated from twin studies with pairs of monozygotic twins (MZ)
and dizygotic twins (DZ), where rMZ and rDZ are the correlations in monozy-
gotic and in dizygotic twins for the same phenotype. Heritability is estimated
as H2 = 2 ∗ (rMZ − rDZ)[66]. Heritability estimates are useful because they help
to determine the potential discriminative ability of predictors based on genetic
variants. Assuming that the heritability estimates reflect the true parameter, phe-
notypic variance explained by linear predictor based on SNPs cannot be higher
than heritability and the upper limit can be achieved only if the true causal SNPs
together with their true effect sizes are known[67]. It has been estimated that the
heritability of breast cancer ranges from 20% to 30%[68] and from 26%-69% for
type 2 diabetes[69, 70], making both diseases eligible for genetic risk score re-
search. In addition, for type 2 diabetes, it has been estimated earlier, that overall
550 independent SNPs are expected to be associated with T2D susceptibility[33],
but only 140 have been found up to date[71]. Similar "expected true number of
SNPs" calculation could not be found for breast cancer in the literature, but cur-
rently, 182 genome-wide significant SNPs have been found[72].
2.3. Genetic risk score
A Genetic risk score (GRS) for ith individual is defined as a weighted sum of





w jXi j, (2.1)
where Xi j denotes the dosage of coded alleles for jth SNP and ith individual and
w j ∈ (−∞,∞) is the weight of the jth SNP. Dosage of ith individual’s coded allele
for jth SNP is Xi j ∈ {0,1,2} if SNP is directly genotyped and Xi j ∈ [0,2] if SNP
is imputed and coded allele dosage is calculated based on genotype probabilities
as described in paragraph 1.5.
It is unclear what is the optimal way of combining the effects of SNPs together
to achieve the best possible predictive value. There are two main questions to be
addressed in the process of computing the GRS: how to choose the set of SNPs
to be included in the GRS and how to choose the weights w j. In general, the
following options are considered
1. Choice of SNPs:
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(a) Use only uncorrelated genome-wide significant (a p-value threshold
set to p < 5 ·10−8 in the GWAS or meta-analysis) SNPs
(b) Use less stringent p-value threshold to select SNPs
(c) Use all available (independent) SNPs
2. Choice of weights w j:
(a) All equal to 1, resulting in a sum of coded allele dosages
(b) Estimated (logistic) regression parameters ŵ j from a discovery GWAS
(c) Somehow modified ŵ j from discovery GWAS to take into account that
SNPs might be correlated with each other
When estimated marginal effect sizes of SNPs from GWAS (choice of weights as
mentioned in 2b) are chosen as weights, we call resulting GRSs single-weighted
genetic risk scores.
2.4. Doubly-weighted polygenic risk score
2.4.1. Motivation
One of the main problems is that true effects of SNPs (wi-s) are unknown. Despite
of the fact that sample size of GWASs are large (reaching hundreds of thousands
of individuals for many traits), the presence of sampling error is unavoidable. That
also means that ordering of the markers and identification of the "top" markers in
terms of Wald type statistic (or p-value) is a subject to uncertainty.
The power to detect association between SNP and phenotype in GWAS de-
pends on sample size, MAF and effect size. SNPs with high minor allele fre-
quency and with large effects are more likely to be picked up by GWAS[73]. But
limiting the GRS to include only few number of highly significant SNPs would
ignore the potential predictive ability of other SNPs. Even though including SNPs
with weaker effect sizes in the GRS seems appealing, the accuracy of their effect
size estimates tends to be low[67], causing the ordering of these SNPs according
to their p-value to be unstable. Furthermore, when imposing a p-value threshold
to select SNPs based on their p-value, one tends to systematically choose SNPs
with effects overestimated by chance.
In other words, this introduces a problem called as winners curse, where by
selecting SNPs according to their p-values we tend to choose more often SNPs
which effect sizes are inflated compared to their corresponding true effects[74].
This is illustrated via simulation study in the Figure 3, where it can be seen that
after setting p-value threshold to 0.00005, out of SNPs with true effect size one,
only SNPs with estimated effect sizes larger than one would be included in GRS
construction.
We propose a new method called doubly-weighting, where the SNP effect
estimate from a GWAS study is additionally weighted by a coefficient that aims
to correct at least partially for the possible overestimation of effect sizes due to
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Figure 3. Comparison of true and estimated effect sizes for 300 SNPs in a simulated
dataset of sample size 10000. The estimates with p-value below the threshold 0.00005
are shown as orange triangles.
winners curse. The idea of the method has been published in the Supplement of
Ref I. We additionally show here with simulations that doubly-weighted GRSs
tend to have a better predictive ability than the single-weighted GRSs.
2.4.2. Notation and methods
Let there be K independent SNPs, X1, . . . ,XK , tested for an association with a phe-
notype Y in a GWAS. For the simplicity, let us assume that SNPs have been stan-
dardized. If the phenotype Y is continuous, an additive linear regression model is
assumed to hold for each SNP:
Y = µ +βiXi + ε, with E(ε|Xi) = 0, for i ∈ 1 . . .K. (2.2)
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In case the the phenotype Y is binary, an additive logistic regression model is
assumed to hold:
logit[P(Y = 1|Xi)] = µ +βiXi, for i ∈ 1 . . .K, (2.3)






As mentioned, β1, . . . ,βK are the true allelic effect sizes of K SNPs having
fixed values. Let ri be the rank of |βi| among |β1|, . . . |βK |, so ri ∈ {1, . . . ,K}.




I(|βi| − |β j| 6 0). The idea of doubly-weighting is to
assume that there are at least k SNPs among K available SNPs having an additive
genetic effect on the phenotype Y and we want to include the SNPs which have
the k largest absolute effect. We do not explicitly assume that only k SNPs with
largest absolute effects are associated with the phenotype. Still, we assume that
the total effect of the SNPs not among the "top k" is not adding any significant
contribution to the genetic risk potentially described by all K SNPs. We also
assume the total effect of the k SNPs on the phenotype is additive and therefore






where fi(k) is defined as
fi(k) = fi(k) (β1, . . .βK) =
{
1 if ri 6 k
0 otherwise
When Y is continuous, we assume that Sk is associated with the phenotype Y
according to the following model:
Y = µ +αSk + ε, with E(ε|Sk) = 0 (2.5)
When Y is binary, we assume
logit[P(Y = 1|Sk)] = µ +αSk, for i ∈ 1 . . .K, (2.6)
For a continuous Y , α = 1 in equation (2.5) if we select wi = βi from equation
(2.2) and the assumption, that Xi are independent, holds. For binary Y , due to
non-collapsibility problem of odds ratios [75], selecting wi = βi from (2.3) may
not result in α = 1.
When wi-s and Xi-s are fixed and we have random variables β̂1, ...β̂K instead







where f̂i(k) = fi(k)
(
β̂1, . . . β̂K
)






We propose an algorithm to estimate the E( f̂i(k)) = P( f̂i(k) = 1) in 2.4.3 and the
estimates will be denoted as πi(k). As wi are also unknown in real life, we need to







2.4.3. Algorithm to identify optimal weights
In reality, it is unknown which SNPs among all available SNPs have the largest
absolute effects for the trait, therefore we need to estimate P( f̂i(k) = 1) somehow.
We propose a following algorithm to obtain estimates πi(k) for given k and
available set (from some GWA study) of β̂1, . . . β̂K and their corresponding stan-
dard errors ŝ1, . . . ŝK :
1. For each i = 1, . . . ,K, draw a random parameter value β̂ (s)i from a normal
distribution with mean β̂i and standard deviation ŝi.
2. Order decreasingly the K estimated independent Wald-type statistics |β̂ (s)i |/ŝi,
and according to the order, assign a rank r(s)i for each |β̂
(s)
i |/ŝi.
3. Repeat steps 1 and 2 M times, to obtain an empirical distribution of ranks
r(s)i , s = 1, . . . ,M for each i.
4. Estimate πi(k) for each i-th SNP is obtained as
1
M ∑
I(r(s)i ≤ k) (proportion
of ranks assigned to the ith SNP that are not larger than k).
We could also choose any value for k, aiming to estimate the effect of k
strongest SNPs with respect to their association with Y . One could try to vary
k around the estimated true number of SNPs affecting the trait, if that estimate
can be found from the literature.
2.5. MetaGRS
For some traits, there are several versions of GRSs already published, often based
on different meta-analyses or computed using different methodologies. Alterna-
tive GRSs might be similar in regard to their predictive ability, however, they do
not need to be highly correlated with each other. MetaGRS is a weighted aver-
age of several existing standardized genetic risk scores which should be based
on different meta-analysis results. The idea was first proposed by M. Inouye and
others[5]. The authors reason that all available genetic risk scores are imperfect
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measures of true genetic risk due to many reasons, including incomplete cover-
age of genome, imputation uncertainty, limited variance explained by SNPs and
errors in effect sizes of SNPs. They argue that it is desirable to improve precision
of genetic risk estimation, as association between disease and risk factor (genetic
risk in this case) measured with error can be attenuated. Combining several GRSs
into one metaGRS could result in more precisely estimated genetic risk.
Mathematically, let Zi1, ...,Zip be p zero mean and unit-variance standardized
genetic risk scores obtained with 2.1 for the ith individual and α̂1, ..., α̂p are effect
size estimates for respective scores from the training set using model 2.5 or 2.6
depending on the type of trait Y . Pearson correlation ρ jk is calculated between Z. j













k= j+1 α̂ jα̂kρ jk
(2.10)
where the effect estimates of GRSs are treated as constants.
2.6. Simulation study I: Comparison of different genetic risk
score’s methods
2.6.1. Overview of simulation’s workflow
To illustrate the benefit of doubly-weighting, the following simulation study is
done.
Let the Y be a phenotype vector with n×1 dimensions. The genotype matrix is
denoted as X with dimensions n× p, where n is the number of unrelated individu-
als and p is the total number of SNPs. SNPs are coded additively, i.e they can take
values 0, 1 or 2. We assume that SNPs are independent (i.e, not in LD) and that
SNP values are drawn from binomial distribution, Xi j ∼ Bin(2, f j), with f j being
the minor allele frequency for the jth SNP. Let Z be the standardized genotype
matrix Zi j = (Xi j−2 f j)/
√
2 f j(1− f j), so that E(Zi j) = 0 and D(Zi j) = 1, where
the Xi j is the number of minor alleles for the ith individuals and jth SNP and f j is
the frequency of the minor allele of jth SNP.





β jZi j + εi (2.11)
so m SNPs are associated with Y and p−m SNPs are not. We generate the ef-






, where σ2g is the variance of total additive





of trait given genotypes is E(Yi|Zi1, ...,Zim) = 0 and the variance of the trait can
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Z2i j + 1−σ2g . According to the to-








So in this kind of setting, trait Y is normally distributed with mean zero and vari-
ance 1. Moreover, as the heritability is the ratio of variance explained by genetic
factors divided by the total variance of the phenotype, then in this kind of simula-
tion setting, the heritability h2 = σ2g .
The simulations followed this pipeline:
1. Heritability h2 = σ2g was set to 0.2 for the first set of analyses and 0.5 for
the second set of analyses.
2. Number of truly associated SNPs m was set to be 100,450,1000 or 10000
for both heritability values.
This means that there were eight combinations of h2 and m to generate Y and
perform a GWA study. To do that, we generated dataset for each h2 and m combi-
nation followingly:
1. Minor allele frequencies f j were generated for j = 1, ...20000 SNPs from
Uniform (0.01,0.5) distribution.
2. The jth SNP for ith individual was generated from Xi j ∼ Bin(2, f j) for i =
1, ...,15000. Matrix X was later standardized.







rest of the 20000−m independent SNPs the effects were set to 0.
4. The outcome variable Y was generated as defined in 2.11, with error term





Finally, GWAS analyses were run using a linear model as defined in 1.2 with-
out any additional covariates besides the single SNP to estimate the effect of each
standardized SNP on Y under fixed h2 and m values. For each SNP, regression
parameter β̂ j, its standard error and p-value were retrieved. In total, after the first
part of simulation, 8 sets of GWAS summary statistics were obtained.
The purpose of the second part of the simulations was to construct GRSs based
on GWAS results and estimate the association between different versions of GRSs
and phenotype in independent datasets. For each combination of h2 and m, 10 test
datasets were generated followingly:
• The same f j were used as in GWA study and SNPs were generated from
Bin(2, f j), j = 1, ...,20000 like before for 3000 unrelated individuals and
then standardized.
• The outcome variable Y was generated as before in 2.11.
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In each dataset, four different types of GRS were constructed by varying the
value of k:
1. The true genetic risk score GRS1, obtained according to 2.4 for a prespec-
ified k using true effects sizes as weights (the beforehand generated βi-s)
and true ranks.
2. The genetic risk score GRS2 calculated using the formula in 2.4 for a pre-
specified k, ie, true ranks ri were used, but as weights, we used estimated
regression coefficients β̂i-s from GWAS.
3. The single-weighted genetic risk score GRSSW as defined in 2.1, including
only k SNPs with smallest p-values from the GWAS and ŵi-s are taken from
the same GWAS as p-values.
4. The doubly-weighted genetic risk score GRSDW defined as 2.9 for a pre-
specified k, with estimated regression coefficients β̂i-s taken from GWAS
and probabilities πi(k) estimated as previously proposed in 2.4.3.
For each score, its estimated effect size and standard error were calculated by
regressing the outcome variable Y in the test dataset on the risk score. Also, the
coefficient of determination - R2- was obtained from each fitted model.
Finally, the entire simulation pipeline was repeated while increasing the GWAS
sample size from 15000 to 30000 to study how GWAS sample size affects the pre-
dictive ability of GRSs.
2.6.2. Results of simulation
Simulations were done separately for two different heritability values: h2 = 0.5
and h2 = 0.2 and by varying the number of SNPs which actually have an effect on
phenotype (denoted as m). GWASs for each h2 and m combination were run twice,
once with sample size 15000 individuals and secondly, with 30000 individuals.
Number of associated SNPs m took values 100, 450, 1000 or 10000 out of 20000
simulated SNPs. Simulation results for different type of GRSs presented below
are obtained by averaging the results of modelling Y and GRSs association over
10 test dataset simulations.
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Figure 4. R2 from the simple regression model with GRS as a single covariate in four
different scenarios - the number of true associations with the trait is either 100, 450, 1000
or 10000 SNPs. In total, 20000 SNPs for 15000 individuals are generated for GWAS.
Results are shown for four types of GRSs. On x axis, the meaning of the logarithmic
value of number of SNPs (value of k) depends on the type of GRS. The heritability of the
trait is set to be 0.2.
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Figure 5. R2 from the simple regression model with GRS as a single covariate in four
different scenarios - the number of SNPs actually associated with the trait is either 100,
450, 1000 or 10000. In total, 20000 SNPs for 15000 individuals are generated for GWAS.
The heritability of the trait is set to be 0.5.
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First, we focus on using GWAS results to compose GRSs, when GWAS sam-
ple size was 15000. It can be seen from Figures 4 and 5, that doubly-weighted
genetic risk scores (GRSDW -s) tend to explain larger proportion of variance than
single-weighted GRSs (GRSSW -s). However, the benefit of GRSDW -s depends on
the number of causal SNPs and heritability of the trait. When the truly associ-
ated number of SNPs is 100, then with both heritability values, GRSDW -s perform
better than GRSSW -s, but slightly worse than GRS2-s. For all other scenarios of
number of causal SNPs (450, 1000 and 10000), the benefit of doubly-weighting
is more clearly present with scenarios of heritability value being 0.5.
For the scenario of 100 causal SNPs and h2 = 0.5, the median difference in
R2 values (i.e median of R2DW −R2SW , taken over all tested k values, DW- doubly-
weighted GRS, SW- single-weighted GRS) is 0.126 (25% percentile = 0.1 and
75% percentile = 0.142) while comparing doubly-weighted and single-weighted
GRSs. In the case of 450 causal SNPs, the median difference in R2 values is 0.041
(25% percentile = 0.034 and 75% percentile = 0.056); 0.025 (25% percentile =
0.02 and 75% percentile = 0.030) while there are 1000 causal SNPs and 0.005
(25% percentile = 0.003 and 75% percentile = 0.007) while number of causal
SNPs is 10000. Results are similar in case of h2 = 0.2 meaning that the benefit
of doubly-weighting compared to single-weighting in regards of improvement in
R2 value is largest with small number of causal SNPs and the benefit decreases
when number of causal SNPs increases. However, the medians of differences in
R2 values are smaller, varying between 0.0008-0.044.
When increasing the number on individuals in GWAS from 15000 to 30000
for the heritability 0.5, then the differences in R2 values diminish very slightly for
the majority of causal SNP scenarios, indicating, that the larger sample size im-
proves the accuracy of GWAS estimated weights and mildly decreases the benefit
of doubly-weighting. For the scenario of 100 causal SNPs, the median difference
in R2 values is 0.107 (25% percentile = 0.086 and 75% percentile = 0.114) while
comparing GRSDW -s and GRSSW -s. In the case of 450 causal SNPs, the median
difference in R2 values is 0.040 (25% percentile = 0.031 and 75% percentile =
0.052); 0.024 (25% percentile = 0.019 and 75% percentile = 0.028) while number
of causal SNPs is 1000 and 0.006 (25% percentile = 0.004 and 75% percentile =
0.008) while number of causal SNPs is 10000. R2 values as well as regression
coefficients for some scores are given in Table 1.
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Table 1. Results from phenotype GRS modelling (formula 2.5), averaged over 10 simu-
lations for h2 = 0.5. Alphas are the estimated regression coefficients for GRS’s.
k SNPs Single-weighted Doubly-weighted R2DW −R2SW
α̂ SE(α̂) R2SW α̂ SE(α̂) R
2
DW
GWAS n=15000 and causal SNP count =100
10 0.974 0.041 0.161 1.301 0.046 0.212 0.05
125 0.905 0.019 0.435 0.989 0.019 0.467 0.032
275 0.801 0.018 0.388 0.968 0.019 0.462 0.074
475 0.717 0.018 0.349 0.941 0.019 0.451 0.102
725 0.641 0.017 0.310 0.909 0.019 0.437 0.126
1025 0.575 0.017 0.278 0.872 0.019 0.420 0.142
2025 0.462 0.016 0.224 0.767 0.018 0.371 0.147
5000 0.345 0.014 0.169 0.570 0.017 0.277 0.108
10667 0.287 0.013 0.141 0.399 0.015 0.195 0.054
GWAS n=30000 and causal SNP count =100
10 0.950 0.040 0.160 1.114 0.043 0.186 0.026
125 0.952 0.019 0.464 0.983 0.019 0.474 0.01
275 0.887 0.019 0.432 0.974 0.019 0.472 0.04
475 0.826 0.018 0.404 0.960 0.019 0.467 0.063
725 0.771 0.018 0.377 0.942 0.019 0.458 0.082
1025 0.718 0.018 0.350 0.920 0.019 0.448 0.098
2025 0.614 0.017 0.299 0.853 0.018 0.415 0.116
5000 0.492 0.016 0.240 0.705 0.018 0.343 0.104
10667 0.429 0.015 0.210 0.549 0.017 0.268 0.058
GWAS n=15000 and causal SNP count =450
10 0.775 0.059 0.054 1.659 0.108 0.073 0.019
125 0.515 0.023 0.147 1.095 0.045 0.167 0.02
275 0.357 0.018 0.121 0.854 0.034 0.173 0.052
475 0.272 0.015 0.101 0.689 0.028 0.167 0.066
725 0.225 0.013 0.090 0.567 0.024 0.155 0.065
1025 0.189 0.012 0.080 0.475 0.021 0.143 0.063
2025 0.135 0.010 0.061 0.323 0.016 0.115 0.054
5000 0.092 0.008 0.045 0.183 0.012 0.078 0.033
10667 0.075 0.007 0.038 0.112 0.009 0.053 0.015
GWAS n=30000 and causal SNP count =450
10 0.826 0.061 0.057 2.658 0.144 0.102 0.045
125 0.478 0.023 0.126 1.165 0.047 0.170 0.044
275 0.360 0.017 0.124 0.879 0.035 0.171 0.048
475 0.269 0.015 0.099 0.695 0.029 0.162 0.063
725 0.213 0.013 0.082 0.566 0.025 0.149 0.067
1025 0.175 0.012 0.068 0.469 0.022 0.136 0.068
2025 0.128 0.010 0.055 0.313 0.017 0.107 0.052
5000 0.087 0.008 0.041 0.173 0.011 0.070 0.030
10667 0.069 0.007 0.033 0.104 0.009 0.047 0.014
GWAS n=15000 and causal SNP count =1000
10 0.556 0.069 eal 0.022 1.400 0.141 0.032 0.012
125 0.336 0.026 0.054 1.000 0.061 0.082 0.028
275 0.273 0.019 0.064 0.744 0.044 0.088 0.025
475 0.215 0.016 0.058 0.586 0.034 0.089 0.031
725 0.175 0.014 0.051 0.480 0.028 0.087 0.036
1025 0.153 0.012 0.049 0.404 0.024 0.085 0.035
2025 0.120 0.010 0.046 0.281 0.018 0.076 0.030
5000 0.092 0.008 0.044 0.169 0.012 0.062 0.018
10667 0.078 0.007 0.040 0.110 0.009 0.050 0.01
GWAS n=30000 and causal SNP count =1000
10 0.514 0.067 0.020 1.965 0.173 0.041 0.021
125 0.326 0.025 0.054 0.926 0.059 0.076 0.022
275 0.249 0.019 0.055 0.698 0.043 0.082 0.027
475 0.207 0.016 0.055 0.557 0.034 0.083 0.028
725 0.168 0.014 0.049 0.459 0.028 0.082 0.033
1025 0.151 0.012 0.049 0.387 0.024 0.079 0.030
2025 0.114 0.010 0.044 0.268 0.018 0.071 0.027
5000 0.085 0.008 0.039 0.158 0.012 0.057 0.019
10667 0.070 0.007 0.035 0.102 0.009 0.045 0.01
It was also investigated how doubly-weighting affects the winner’s curse prob-
lem. Effect estimates β̂i-s were taken from GWASs with sample size 15000. Then,
for each k value, the difference between true and estimated effects (β̂i−βi) was
characterised. This means that for single-weights, β̂ from GWAS for k SNPs with
smallest p-values were taken and and their difference with true effect sizes cal-
culated (i.e (β̂i−βi) for k SNPs). For doubly-weighted weights, the probabilities
πi(k)-s were estimated and β̂i-s modified by them. Then the difference between
true effects and estimated effects were calculated (i.e (β̂i ·πi−βi) for K SNPs).
Results for some k values are in Table 2. "SD" stands for standard deviation.














(β̂i−βi) SD(β̂ −β )
h2 = 0.2 and causal SNP count =100
10 -3.26 ·10−5 2.35·10−3 1.89·10−3 9.02·10−3
75 -1.73 ·10−6 1.09·10−3 2.59·10−3 1.77·10−2
125 -1.00 ·10−6 1.09·10−3 4.23·10−3 2.03·10−2
275 4.24 ·10−7 1.22·10−3 1.87·10−3 2.10·10−2
475 1.85 ·10−6 1.44·10−3 5.75·10−5 2.04·10−2
725 3.36 ·10−6 1.71·10−3 -2.95·10−4 1.95·10−2
1025 4.91 ·10−6 2.00·10−3 -1.89·10−4 1.87·10−2
2025 8.90 ·10−6 2.78·10−3 7.98·10−5 1.68·10−2
5000 1.87 ·10−5 4.34·10−3 1.77·10−4 1.38·10−2
10667 3.19·10−5 6.13·10−3 9.17·10−5 1.80·10−2
h2 = 0.2 and causal SNP count =1000
10 6.18·10−6 3.27·10−3 2.84·10−2 6.30·10−2
75 1.43·10−5 3.32 ·10−3 3.53·10−3 5.68·10−2
125 1.85·10−5 3.39·10−3 3.68·10−3 5.38·10−2
275 2.64·10−5 3.65·10−3 4.65·10−3 4.95·10−2
475 3.39·10−5 4.03·10−3 3.47·10−3 4.65·10−2
725 4.02·10−5 4.50·10−3 1.10·10−3 4.40·10−2
1025 4.53·10−5 5.04·10−3 1.96·10−3 4.19·10−2
2025 5.59·10−5 6.59·10−3 1.05·10−3 3.74·10−2
5000 6.34·10−5 9.87·10−3 2.89·10−4 3.06·10−2
10667 6.21·10−5 1.38·10−2 1.10·10−4 2.40 ·10−2
It can be seen from 2 that the winner’s curse problem is reduced (but not com-
pletely corrected) while using doubly-weighting and the difference is more notice-
able for smaller k values. Standard deviations of differences between estimated
weights and true weights are also smaller for doubly-weighted weights. Results
were similar for h2 = 0.5 and are therefore not separately presented.
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3. RESULTS AND DISCUSSION
3.1. General overview of datasets used in this thesis
During this PhD project, several datasets were used to develop genetic risk scores
and investigate their features and associations with different variables. A broad
overview of them is given in this paragraph and additional details are given in the
specific sections of the corresponding references.
Estonian Biobank (EstBB or EGCUT) hosts a cohort of∼52000 participants
(34% are men and 66% women) aged 18 and older. Majority of the participants
were recruited between 2002 and 2011. Cohort includes adults from all counties
of Estonia and it accounts for approximately 5% of the Estonian adult popula-
tion during the recruitment period[76]. Participants gave extensive information
regarding their anthropometric, genealogical, lifestyle and educational character-
istics as well as their medical history. A broad informed consent signed by partic-
ipants allows the data to be used for various research purposes and it also enables
follow-up of participants via linkage with national health-related databases and
registries[77].
Genotyping has been done in several stages over time using different geno-
typing arrays. By the end of 2017, the genomes of most participants were either
genotyped or sequenced, most of them with Illumina’s Infinium Global Screening
BeadChip. Analyses during this thesis were done using genetic data imputed with
either 1000G or Estonian WGS data as a reference panel.
UK Biobank (UKBB) is a cohort study with∼500 000 individuals aged 40-69
recruited during 2006-2010[78] in UK. Both deep phenotypic and genetic data has
been collected, including biomarkers from blood and urine and images of brain
and the body[79]. Participants are followed-up via linking to their health-related
records. Majority of participants have reported to be of European origin[79]. In-
dividuals are genotyped with two different genotyping arrays[79] and imputation
used in this thesis had been done with Haplotype Reference Consortium (HRC)
panel as reference. In this thesis, only women not included in the GWAS sample
(∼46000 women) are used to assure independence of discovery and validation
dataset.
The 1000 Genome project (1000G) includes in total 2504 individuals from 26
populations sampled from Africa, East-Asia, South-Asia, Europe and Americas[13].
All individuals were sequenced with whole-genome sequencing. The idea of the
project was to provide characterization of the genetic variation in human genomes,
both common and rare. The project also serves as a global reference for genotype
imputation for many populations. However, phenotype information is not publicly
available for this sample.
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3.2. Polygenic risk scores for type 2 diabetes
3.2.1. Short description of materials and methods
The study planned to obtain the SNP effect sizes from meta-analysis for type 2 di-
abetes (T2D) by Morris et al.[33], but as subset of EstBB sample was included in
this study, we first rerun the meta-analysis to exclude EstBB data as we intended
to use all available genotypes in EstBB for GRSs development. The meta-analysis
results without Estonian sample were then used in the following analysis. Inde-
pendent set of SNPs (r2 ≤ 0.05) was obtained via clumping[80]. Clumping is a
procedure that needs a GWAS summary statistics file and a reference file of WGS
data or genotype dataset. Steps of clumping include taking a list of GWAS SNPs
and their p-values and first sort them in an increasing order according to the p-
value. Then it selects an index SNP with the smallest p-value from that list and
calculates pairwise correlations between index SNP and all other SNPs in a list
which are not physically further from each other than a predefined distance. All
SNPs, which squared pairwise correlations with index SNP are larger than a user
defined threshold, are excluded from the original GWAS list. Index SNP is kept.
Next index SNP is then selected (second smallest p-value in the remaining GWAS
list) and previous steps are repeated. In the end, clumping results in a list of un-
correlated (up to users definition) GWAS index SNPs. In addition, SNPs were
also filtered by their imputation quality and minor allele frequency in our dataset,
resulting in a set of 7502 SNPs for GRSs construction. More details about data
management in [Ref I, Supplementary Materials].
A set of 10273 genotyped individuals (descriptive information in Ref I, Table
1) with 1181 prevalent T2D cases present and 386 incident T2D cases obtained via
linking to National Health Insurance Fond and Causes of Death Registry was used
in this article. The average follow-up time was 5.36 years. Baseline phenotype
data including age, gender, body mass index (BMI), physical activity, etc as well
as metabolic profiles for a subset of 6064 individuals were used in this analysis.
We constructed single-weighted GRSs (denoted as GRSk) and doubly-weighted
GRS (denoted as dGRSk) by varying the number of k and compared them by mod-
elling the prevalent status of T2D with logistic regression model adjusted for age,
sex and genotyping platform and in the additional setting, also for BMI. Differ-
ent version of GRSs were compared with Cox likelihood ratio test for non-nested
models[81]. We investigated the effect of chosen GRS from the first step by mod-
elling incident T2D, all-cause mortality and cardiovascular mortality using age
as time scale while accounting for known classical risk factors of T2D among
individuals aged 35-79.
Associations between classical risk factors and chosen GRS among diabetics
and non-diabetics were investigated via linear regression analysis. Finally, incre-
mental value of GRS was investigated with AUC and Harrell’s c-statistics and via
characterising properties of 5-year risk estimates for type 2 diabetes from models
with and without GRS using reclassification indexes. Harrell’s c- statistic aims
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to estimate the probability of concordance between predicted and observed re-
sponses in survival setting[82]. Let X1,X2... be the survival times of individuals
in a given population. Let T be the time point after which all survival times are
truncated, so individuals who do not develop an event by the time point T , have
their survival time set to T . For a time point T , we will have two categories:
events (who developed an outcome during follow-up) and non-events (who did
not develop an outcome during follow-up). Let Y1,Y2... be predicted probabilities
of survival for the same individuals for any fixed time point. We take under con-
sideration all pairs of subjects (i,j), assuming i < j, to avoid repetition. A pair is
said to be concordant if Xi < X j and Yi < Yj or Xi > X j and Yi > Yj. Only pairs
of individuals, in which at least one is event, are usable. The c-statistic is defined
as c = P(Yi < Yj|Xi < X j)[83]. In a sample, it can be estimated followingly: Let
there be a sample of n individuals, xi-s their observed survival times and yi-s their
predicted probabilities of surviving until a given time point t, i = 1, ...n. Let us
define ci j which takes value 1 if xi < x j and yi < y j or xi > x j and yi > y j and 0






where q is the number of all usable pairs[83]. Value 0.5 shows that there is no
predictive discriminative ability and value 1 shows perfect discrimination between
individuals with different outcomes.
Net reclassification index (NRI) aims to quantify how well a new model cor-
rectly reclassifies subjects compared to old model[84]. Probabilities of having an
event during fixed time of period from both old and new model are acquired for
all individuals. Among events, NRI is defined as the difference in proportion of
events whose probabilities are higher with new model compared to old model and
the proportion of events whose probabilities are lower with the new model than
with the old model. Among non-events, NRI is defined as the difference in pro-
portion of non-events whose probabilities are lower with new model compared to
old model and the proportion of non-events whose probabilities are higher with
the new model than with the old model.
3.2.2. Associations of different GRSs and status of type 2 diabetes
Both BMI adjusted and unadjusted models were fitted to compare different ver-
sions of GRSs. No single-weighted score showed so high likelihood ratio test
statistics [Ref I, Figure S1] as double-weighted scores with 300 < k < 2000. The
highest log-likelihood was reached with dGRS1400 for BMI-unadjusted models
and dGRS800 for BMI-adjusted models [Ref I , Table 2]. As dGRS1000 provided
a fit that was not significantly different (Cox test p > 0.05) from the best-fitting
GRSs either BMI adjusted or unadjusted models, it was chosen for all the fol-
lowing analyses. Up to our best knowledge, 65 SNPs included in the GRS by
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Talmud and colleagues[85] was the most SNPs used to compose GRS for T2D
before our study. Talmud et al. reported that OR corresponding to 1 standard de-
viation was 1.43 (95% CI 1.33-1.54) whereas in our study for dGRS1000, OR per
1 SD was 1.56 (95% CI 1.45–1.68) in the BMI unadjusted model and 1.59 (95%
CI: 1.46–1.72) in the BMI adjusted model. We also compared the GRS quintiles
while analysing incident T2D, showing that the difference in hazards between
lowest and highest quintile is more than threefold(HR = 3.45, 95% CI: 2.31–5.17)
[Ref I, Table 3]. The dGRS1000 showed also an association with all-cause and
cardiovascular mortality.
We investigated associations between dGRS1000 and T2D risk factors sepa-
rately in prevalent T2D cases and controls. In the sample with individuals without
prevalent T2D, dGRS1000 showed positive association with triglycerides, plasma
glucose levels and waist-hip ratio and negative association with high density lipopro-
tein levels [Ref I, Table S5].
3.2.3. Analysis of incremental value of GRS
Harrell’s c-statistic increased by 1.2% (95% CI 0.004-0.023) after adjusting Cox
proportional hazard model with BMI, waist circumference, waist-hip ratio, his-
tory of hypertension, history of high blood glucose, physical activity level, smok-
ing, fruit and vegetable consumption additionally for dGRS1000. Greater benefit
of GRS was seen among individuals with BMI ∈ (25,35), were the increase of
c-statistic was 2.1% (95% CI 0.006-0.039) [Ref I, Table S6]. Even though the
added benefit of GRS is relatively low, majority of previous studies (given in the
review by[60]) comparing discrimination of clinical risk models with and without
including genetic risk scores for incident T2D had reported either no improve-
ment in discrimination or it remained under 1%. One of the possible explanation
for these findings could be that the risk factors also have genetic background (such
as BMI for instance) and if the genetic risk score captures that, adjusting for both
might not give additional information. The other reason could be that most of the
scores mentioned in[60] included less than 20 SNPs and therefore might have had
a limited predictive ability in the first place.
To study reclassification, status of incident T2D was determined after up to
5 years of follow-up. We investigated 5-year predictions from models with and
without dGRS1000. The net reclassification index for T2D events was 0.115 (95%
CI 0.02-0.23) and for non-events, 0.209 (95% CI 0.182-0.23), showing that non-
events gain more benefit in terms of prediction accuracy than events. Similar re-
sults were demonstrated in study by Talmud et al.[85] were they reported that
adding GRS with 65 SNPs to a 10-year risk estimate composed of age, sex,
parental history of T2D, BMI, blood pressure, HDL cholesterol, triglyceride, and
fasting glucose level increased the event NRI by 13% and non-event NRI by 17%.
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3.3. Polygenic risk scores for breast cancer
3.3.1. Description of materials and methods
Both Estonian (n = 32557) and UK Biobank (n = 43827) women (not included
in UKBB GWAS data) are used during this analysis. Estonian Biobank data was
divided into two parts: 1) derivation set with all prevalent breast cancer (BC)
cases (317) and 2000 randomly selected controls and 2) validation set with 30240
women, including 308 incident BC cases. For UKBB, both status of BC is deter-
mined via combination of diagnosis linked from UK National Cancer Registries
and self reported information, resulting in 3157 cases.
As meta-analysis summary results for BC were publicly unavailable until the
end of 2017, genetic risk scores were limited to very few (less than 100) SNPs.
We identified 2 previously published GRSs from the literature with originally 86
and 77 SNPs, but 70 and 75 SNPs of those were available respectively with high
imputation accuracy in Estonian Biobank. Likewise to other complex diseases,
we hypothesised that including more SNPs into genetic risk score would improve
its predictive ability.
In 2017, Neale’s Lab performed GWASs using∼337000 unrelated individuals
of British ancestry and made the results for more than 2000 phenotypes (including
self reported BC) publicly available[86]. At the same time, Breast Cancer Associ-
ation Consortium published their meta-analysis results performed with more than
100 000 cases and controls of European ancestry. Both summary statistics files
were available for 11 million SNPs. We developed GRSs with both summary
statistics files using PRSice[87] by first clumping the SNPs to obtain independent
set of them and then varying p-value threshold for inclusion into GRS. As a next
step, we tested prevalent BC status-GRS association in the case-control subset of
Estonian Biobank with 318 BC cases and 2000 controls and chose the GRS from
each study with the smallest p-value for further investigation and denoted them as
GRSUK and GRSONCO. Several versions of metaGRSs as described in section 2.5
were composed (see Figure 6). Association of all four GRSs and three metaGRSs
were assessed in both UKBB with logistic regression model and EstBB’s valida-
tion set with Cox proportional hazard model. Incremental value of GRSs were
investigated by comparing Harrell’s c-statistics from models adjusted for 10-year
risk estimates obtained via National Cancer institute algorithm alone and together
with different versions of GRSs. We also assessed the joint effect of family his-
tory status of breast cancer and genetic risk score in UKBB. Detailed overview of
the workflow is given in Figure 6.
3.3.2. Comparison of predictive ability of GRSs
GRS75 and GRSONCO had the strongest effects on BC in both EstBB (OR per 1 SD
1.38, 95% CI1.22-1.57 and 1.44, 95% CI 1.27-1.64 , respectively) and in UKBB
(OR per 1 SD 1.48, 95% CI 1.43-1.53 and 1.51, 95% CI 1.46-1.57) [REF II: Sup-
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Figure 6. Overall workflow of breast cancer genetic risk score development and analyses.
plementary Table 2]. Combining these two score into metaGRS2 resulted in the
GRS with the strongest association in both cohorts [Ref II, Table 1, Supplemen-
tary Table 2]. Even more, adding metaGRS2 to 10-year risk estimate taking into
account other known risk factors (such as age, age of menarche, age of first child-
birth, ethnicity, etc) for BC[88] increased the Harrell’s c-statistic by 3.8% (from
0.677 to 0.715).
We looked into if and how the effect of GRS attenuates after adjusting for
family history using UKBB data. Both family history of BC and any version of
genetic risk score were statistically significant predictors for the status of prevalent
BC, and including family history in the logistic regression model only marginally
decreased the effect of any GRS [Ref II: Table S2]. The importance of both family
history and genetic risk score is shown in Figure 7. Mavaddat et al.[89] also
showed that GRS and family history modify BC risk together, adjusting for both
attenuates the effect of family history by 12.6%.
3.3.3. Non-uniqueness of polygenic risk scores
Depending on a GWAS that is used to develop GRSs, different and not necessarily
highly correlated GRSs can be produced for the same disease [Ref II: Supplemen-
tary Figure 2]. We hypothesize that GRSs might reflect the effects of different bi-
ological pathways or risk factors of the disease. For example, higher GRSUK was
associated with lower body mass index and waist circumference, more strongly
among younger women whereas GRSONCO seemed to be weakly associated with
40
Figure 7. Prevalence of breast cancer in different metaGRS2 categories depending on
status of family history (FH) of breast cancer in UKBB data.
the status of smoking [Ref II: Supplementary Table 3-4]. The negative association
between GRSUK and BMI among younger women is biologically plausible, as low
BMI has been shown to be a risk factor for breast cancer among pre-menopausal
women[90, 91], even though the biological mechanism behind it is still unknown.
The fact that different GRSs for the same disease might not agree with each
other has implications to genetic feedback and genetic risk based targeted screen-
ing. For example, individuals belonging to the top 5% with one GRS do not
necessarily belong there with the other GRS [Ref II: Figure 2; Figure 8]. The
overlap depends on the level of correlation between the two scores.
Currently, there are pilot programs going on in the world (like RITA in Estonia
or WISDOM in US[92]), targeting women for earlier screening solely based on
their value of GRS. This non-uniqueness of GRSs is an important issue for these
type of projects and both feedback receivers and medical staff should be aware
that GRSs at this state are still proxies of true genetic risk and are subjected to
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Figure 8. Scatter plots of different GRS. Red lines indicate the 95th percentile of the
GRS and the blue line the median of GRS. Individuals belonging to top 5% category with
one GRS and below median category with other are denoted with red dots.
change in the future. However, when GRS is not used alone, but is only one
variable in the absolute risk model with similar effect size than other risk factors,
its varying might not be an important problem.
Even though combing GRSs into one metascore resulted in a best predicting
genetic estimator for BC, it remains unclear if using metaGRS instead of several
different genetic risk scores is always the best practice – if biological mechanisms
can be assigned to GRSs, more efficient prevention could be attributed. It seems
also plausible, that optimal GRSs for different subtypes of diseases are not al-
ways the same. This has been recently demonstrated for breast cancer, where best
predicting GRSs for BRCA1 and BRCA2 carriers were different and depended
on whether the SNPs in GRS were associated with estrogen-receptor positive or
negative breast cancer[93]. However, a lot more research needs to be done in
subtype-specific GRS area before more conclusive inference can be drawn.
3.4. Polygenic risk score distributions in different ancestral
populations
3.4.1. Description of materials and methods
2244 samples from the Estonian Biobank with whole-genome sequencing data
available and 1000G Project data from phase 3 release with 2504 individuals from
5 populations (Europeans (EUR), East-Asia (EAS), South-Asia (SAS), Africa
(AFR) and Americas (AMR)) were used in this analysis. We identified SNPs from
both datasets for two published genetic risk scores - GRST 2D and GRSCHD. In to-
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tal, for type 2 diabetes score, 7395 SNPs and for coronary heart disease, 45996
SNPs were used, respectively. Both GRSs had been developed based on GWA
study mainly using European ancestry samples. Genetic risk scores were calcu-
lated with PLINK[80] and the distribution of both scores were plotted separately
for all populations. Also, quintiles of GRSs depending on population were com-
pared. Finally, principal components for both datasets were calculated to explore
associations between them and genetic risk scores.
3.4.2. Characterization of distributions of polygenic risk scores in
populations
Average GRST 2D in Europeans is -0.73 (95% CI -0.69...-0.61) whereas average
GRST 2D among African population is 1.57 (95% CI 1.54-1.60)[Ref III: Table
1]. However, similar prevalences of type 2 diabetes[94] across different ancestral
groups (age standardized prevalence 7.1% in African region vs 7.3% in European
region) do not show the same disparity as genetic risk scores. Similar phenom-
ena has been recently shown for schizophrenia[95, 96]. Bitarello and Mathieson
also show that GRS for height developed based on UKBB GWAS effect estimates
explains 1.7% of height variation in African Americans, compared to 5.5% in Eu-
ropean Americans[97], raising an important question about the transferability of
the GRSs between populations.
There are several possible explanations why higher GRS values in one pop-
ulation might not result in higher disease prevalence. One of them is that true
effect sizes for the same SNP vary between populations. For example, it has
been shown that there are SNPs which effects on total cholesterol depend on the
ethnicity[98]. Furthermore, Brown et al.[99] compared SNP effect estimates ob-
tain from GWASs based on individuals of European descent and from GWASs
based on individuals of East-Asian descent. They showed that correlation between
effect sizes for rheumatoid arthritis was 0.436 and for type 2 diabetes 0.606. How-
ever, heterogeneity of effect sizes for a SNP can also occur when the true effect
sizes for a certain causal SNP are the same but the linkage disequilibrium struc-
tures differ between studies and therefore the level of correlation between tagging
SNPs and causal SNPs differs as well, causing observed effects of tagging SNPs
to vary[46, 95].
3.5. Predictive ability of non-genetic risk scores for
atherosclerotic cardiovascular diseases and death in Estonian
Biobank
3.5.1. Description of materials and methods
Even though my thesis otherwise focuses on genetic risk scores, non-genetic "risk
scores" -risk assessment tools - also exist and research to study their predictive
ability in different scenarios is ongoing. Risk assessment tools are often used to
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support clinical decision making in primary prevention. There are several tools
out there, all predicting partially overlapping endpoints. Three widely used risk
scores were selected to assess their predictive ability in Estonian Biobank:
• The American Heart Association guideline (ACC/AHA) recommends a tool
called PCE which estimates 10-year risk of developing hard atherosclerotic
cardiovascular disease (ASCVD) (first fatal or non-fatal myocardial infarc-
tion or stroke and coronary heart disease death) on individuals aged 40–79.
• NICE guideline recommends a tool called QRISK2. QRISK2 was devel-
oped in UK and it estimates 10-year risk of developing fatal or non-fatal
ASCVD (first diagnosis of coronary heart disease, stroke or transient is-
chaemic attack) on individuals aged 25–84 without type 1 diabetes.
• SCORE is a tool which estimates 10-year risk of cardiovascular mortality
for individuals aged 40+ without chronic kidney disease or diabetes. It
was developed based on data from 12 European countries and it is a tool
recommended by the European Society of Cardiology (ESC).
Age, sex, systolic blood pressure, smoking status and total cholesterol are in-
cluded in all risk score algorithms. Additionally, high-density lipoprotein, dia-
betes status, usage of antihypertensive medication and ethnicity are included in
PCE and QRISK2. Finally, QRISK2 also includes family history of ASCVD,
body mass index, social deprivation (using UK postcode as a proxy) and statuses
of many diseases (such as rheumatoid arthritis). See also Figure 9.
Subsets of data corresponding to each score specific guidelines were defined
as well as all three different endpoints of scores (Ref IV, Figure 1). Only individ-
uals with measured metabolites available at recruitment were used in this study.
Information to define endpoints and follow-up time were retrieved from National
Health Insurance Fund and Estonian Causes of Death Registry (details in Ref IV,
supplement).
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Figure 9. Venn diagram showing what risk factors are included in the risk scores and how
risk factors are overlapping between scores
Predictive ability of all three scores was characterized with Harrell’s c-statistic
and standardized incidence ratios. Standardized incidence ratio (SIR) was defined
as expected number of events divided by observed number of events. The ex-
pected number of events for each score specific outcome was calculated as the
sum of 7-year risk estimates. To obtain 7-year risk estimates, original 10-year
risks were modified using a constant hazard assumption. However, the modifi-
cation depended on the status of the endpoint: for events, either 7-year risk or
risk estimate corresponding to maximum follow-up length (if maximum possi-
ble follow up was less than 7 years from recruitment) was calculated. For non-
events, the risk scores corresponded to the actual follow-up time. Viallon[100] has
shown, that this method described above is unbiased compared to the modifica-
tion method, where the risk scores are calculated for the actual length of follow-up
regardless of the endpoint status. Surprisingly, the latter method is very popular
in the literature, but it systematically lowers the expected number of events, bias
depending on the proportion of events in the data (more details about methods in
Ref IV, Supplement).
3.5.2. Predictive ability of risk scores in Estonian Biobank
Out of 8830 individuals, 4356, 7191 and 3987 individuals were eligible accord-
ing to the guideline-specific criteria for the calculation of PCE, QRISK2 and
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SCORE. During follow-up, which was censored after 7 years, 220 PCE-specific,
671 QRISK2-specific and 94 SCORE-specific outcomes occurred (Ref IV, Fig-
ure 1). Among three scores, SCORE showed the highest discriminative ability
(Harrell’s c = 0.865) and PCE the lowest (Harrell’s c = 0.778) for score specific
outcomes (Ref IV, Table 1). Regarding calibration, SCORE (SIR = 0.99, 95% CI
0.81 to 1.21) and PCE (SIR = 1.03, 95% CI 0.90 to 1.18) seemed to be well cal-
ibrated in Estonian Biobank, however, QRISK2 severely underestimated the the
number of cases (SIR = 0.52, 95% CI 0.48 to 0.56) (Ref IV, Table 2).
While developing SCORE, the researchers did not use the status of diabetes for
exclusions as suggested by the guidelines, as the information was not available
for some cohorts. We also investigated, how inclusion of diabetics changes the
discrimination and calibration of SCORE. When individuals with diabetes were
included in the dataset, the overall SIR of SCORE decreased from 0.99 to 0.86
(95% CI 0.71-1.04). Among women, SIRs decreased the most - when including
diabetics into the dataset, SCORE predicted 26% less cases than observed (48.1
expected vs 65 observed) compared to 14% less cases than observed without di-
abetics (38.8 expected vs 45 observed). Discrimination remained very similar
among women and decreased among men (Ref IV, Supplement). These results
support the recommendations by the European prevention guideline that diabetics
should automatically categorize into a high or very high risk group, in whom the
risk by SCORE is underestimated.
We also investigated how well for QRISK2 education level works as a proxy
for level of social deprivation (estimated with UK postal code in QRISK2 cal-
culator) in Estonia. The substitution was done as suggested by[101]. The pre-
dictive ability of QRISK2 was investigated with education level as a proxy and
in a second scenario, leaving it blank (ie, using average value 0) as proposed
by the developers of calculator in case UK postal code is unknown. The c-
statistic’s remained very similar. Even though estimated number of events in-
creased marginally, QRISK2 still severely underestimated the risk of developing
fatal or non-fatal ASCVD (Ref IV, Supplementary table 5), overall indicating that
the level of education is not a very useful proxy for social deprivation in Estonia.
We also compared the treatment recommendations based on guideline-specific
criteria. Depending on the combination of risk factor levels, each guideline gives
suggestions regarding statin distribution: it can either be recommended, consid-
ered or deemed unnecessary. NICE guideline (QRISK2) was found to be most
conservative and ESC (SCORE) most liberal while suggesting use of statins (Ref
IV, Figure 3). However, statins for primary prevention were recommended to al-
most half of the men and quarter of women under investigation, illustrating high
risk levels of ASCVD in Estonia.
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4. CONCLUSION
The importance of prevention of common complex diseases has arisen as an
important topic in personalized medicine. Interest in genetic predictors has in-
creased, as they allow identification of individuals with higher predisposition for
a trait already in an early age. One option to estimate individual’s genetic predis-
position for a common complex disease is via genetic risk scores.
At the beginning, genetic risk scores were usually a sum of risk alleles ac-
counting for a few well established trait-associated SNPs. Pretty soon the idea
arose to weight SNPs differently based on findings from GWASs, however, the
scores were still limited to SNPs which had achieved genome-wide significance.
In the beginning of this thesis, the largest GRS for type 2 diabetes included 65
SNPs and we set a goal to further improve the predictive ability of a GRS for type
2 diabetes.
Doubly-weighting is an alternative method to single-weighting while construct-
ing genetic risk scores. Instead of setting a p-value threshold to include SNPs into
the GRS as done with single-weighting, all uncorrelated SNPs can be included
from GWAS. The benefit of doubly-weighting (as shown with simulations) de-
pends on the heritability of the trait as well as number of causal SNPs. In the first
article of this thesis, doubly-weighted GRS is a systematically stronger predictor
for type 2 diabetes compared to single-weighted versions of GRSs in Estonian
Biobank.
Over the years, many GWASs and meta-analyses are performed for the same
trait and their summary statistics files are often publicly available. Several param-
eters of these studies vary: sample size, inclusion criteria of individuals, charac-
teristics of samples as well as genotyping platforms used to generate the data or
imputation reference used to impute the data. But this means that different GRSs
can be constructed using different GWA studies to select both SNPs and weights.
Therefore, the study that one uses as a base to construct GRSs will affect why and
how GRS will be predicting a trait. Consequently, GRSs composed for the same
trait based on diffent studies might not be highly correlated with each other. This
phenomena is observed in the second article of this thesis for breast cancer, where
four different base files are used to generate GRSs. To achieve the best predict-
ing GRS, an idea of combining GRSs based on different studies is implemented
and it results in a metaGRS combining two GRSs into one. However, the non-
uniqueness of GRSs is an important issue especially for projects trying to stratify
individuals for prevention solely based on GRS.
Another important aspect influencing the predictive ability of GRSs is the sim-
ilarity of discovery and validation population. This is investigated in the third
article, where it is showed that the distributions of GRSs for type 2 diabetes and
coronary artery disease are different within different ancestral populations. Un-
fortunately, due to lack of phenotypes for the 1000G project data, we were unable
to compare the predictive ability of the same GRS in different populations. How-
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ever, other scientists have now shown that at least for schizophrenia and height,
the GRSs developed using GWASs mainly based on European ancestry samples
do not show the same predictive power for Europeans and African Americans,
raising an important question about the overall transferability of GRSs between
populations.
Finally, non-genetic risk scores for ASCVD are validated in the Estonian Biobank
data. The idea was to investigate if and how the risk algorithms perform in their
original form in Estonian Biobank. We found that the discriminative ability of
all three scores were good. PCE and SCORE were well calibrated, but QRISK2
estimated almost twice as less cases than observed. We also compared the statin
treatment recommendations based on guideline specific criteria. The most con-
servative out of three of them was NICE (QRISK2) and the most liberal was ESC
(SCORE). However, statins for primary prevention were recommended to almost
half of the men and quarter of women under investigation, illustrating high risk
levels of ASCVD in Estonia.
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SISUKOKKUVÕTE
Riskiskoorid ja nende prognoosivõime
komplekshaiguste jaoks
Võrreldes kümne aasta taguse ajaga on nii genotüpiseerimine kui ka sekvenee-
rimine oluliselt odavamaks muutunud (10 miljonit dollarit 2007. a ühe genoomi
sekveneerimiseks võrreldes ∼1000 dollariga 2017.a[102]). Selliste tehnoloogia-
te odavnemine on plahvatuslikult kasvatanud geneetiliste andmete valimimahtu,
võimaldades nende ja olemasolevate meditsiiniliste ning fenotüübiliste andmete
kombineerimisel paljude tunnuste ning haiguste geneetilist tausta põhjalikult uu-
rida. Kuigi enamike tunnuste ja haiguste geneetiline arhitektuur on veel täielikult
avastamata, töötatakse viimastel aastatel pidevalt selle kallal, et olemasolevaid ge-
neetilisi teadmisi juba kuidagi inimeste tervise heaks rakendada.
Kõige uuritumad geneetilise varieeruvuse allikad on ühenukleotiidilised polü-
morfismid (SNPd). Enamasti on sagedased SNPid üsna väikese mõjuga ning see-
tõttu ühe SNPi kasutamine mingi tunnuse prognoosimiseks pole mõttekas. Kuid
paljude SNPide efektide kombineerimisel saadud tunnus, mida nimetatakse ge-
neetiliseks riskiskooriks, on aga mitmete komplekshaiguste nagu teist tüüpi dia-
beet, rinnavähk või südame isheemiatõbi geneetilise eelsoodumuse hindamiseks
osutunud kasulikuks. Ka algoritmide, mida tavaliselt kasutatakse nimetatud hai-
guste 10a haigestumistõenäosuse hindamiseks, ennustusvõime on geneetilise ris-
kiskoori lisamisel oluliselt paranenud.
Geneetiline riskiskoor on erinevate SNPide kaalutud alleelidooside summa.Antud
töö eesmärgiks oli selgitada, milline võiks olla optimaalne SNPide ning nende
kaalude valik sellise skoori moodustamisel. Kaua aega oli kõige populaarsem
(ning ka arvutuslikult lihtsaim) viis väheste, ülegenoomselt oluliste SNPide kaasa-
mine ülegenoomsetest assotsiatsiooniuuringutest või suurtest meta-analüüsidest,
kas kaalumata alleelidooside summana või siis kasutades kaaludena ülegenoom-
setes uuringutes hinnatud regressioonikordajaid. Käesoleva töö eesmärk oli uuri-
da, kas geneetiliste riskiskooride ennustusvõimet saaks parandada, suurendades
skoori kaasatud SNPide hulka ja korrigeerides nende kaalusid.
Töös tutvustatakse uut SNPide kaalumismeetodit - topeltkaalumist, kus SN-
Pi kaalu modifitseeritakse vastavalt empiiriliselt hinnatud tõenäosusele, et antud
SNP kuulub fikseeritud suurusega SNPide hulka, millel on uuritava tunnusega
tegelik seos. Topeltkaalumise eeliseid näidatakse nii simulatsioonide abil kui ka
pärisandmete peal, uurides Eesti Geenivaramu andmeteid.
Töös uuritakse ka erinevaid geneetilisi riskiskoore rinnavähile ning leitakse, et
mitme erineva geneetilise riskiskoori kombineerimine üheks skooriks aitab genee-
tilist eelsoodumust rinnavähi jaoks kõige paremini hinnata. Samas tuleb esile, et
erinevad geneetilised riskiskoorid, mis haigusega seotud, ei pruugi olla üksteise-
ga korreleeritud ning seetõttu sõltub geneetilise eelsoodumuse hindamine tugevalt
geneetilise riskiskoori valikust ega ole ühene hinnang.
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Edasi uuritakse töös geneetiliste riskiskooride jaotust erinevates populatsioo-
nides ning leitakse, et üksteisest geneetiliselt kaugel asuvate populatsioonide ris-
kiskooride jaotused on erinevad. Selline teadmine näitab, et geneetilise eelsoodu-
muse määramisel geneetilise riskiskoori abil ei saa erinevaid populatsioone koos
käsitleda. Samuti on hiljuti näidatud, et ühes populatsioonis välja töötatud riskis-
kooril ei pruugi teises populatsioonis prognoosivõimet olla[97].
Viimaks valideeritakse kolme erinevat mittegeneetilist riskiskoori TÜ Eesti
Geenivaramu andmetes. Eestis on peamiseks surmapõhjuseks südameveresoon-
konna haigused ning eriliselt murettekitav on see meeste hulgas, Eesmärgiks oli
uurida, kas ja kuidas töötavad erinevad tuntud südameveresoonkonna haiguste
jaoks mõeldud riskialgoritmid Eesti andmetel. Leidsime, et SCORE ja PCE algo-
ritmid olid hästi kalibereeritud, kuid QRISK2 alahindas riski, prognoosides pea
kaks korda vähem ASCVD juhte kui tegelikult tekkis. Erinevate riskiskooride-
ga kaasas käivad ravijuhised erinevad oma statiinide määramise eeskirja poo-
les. Nende võrdlusel selgus, et NICE (QRISK2) on kõige konservatiivsem ning
ESC(SCORE) ravijuhis kõige liberaalsem. Kahjuks soovitasid kõik kolm ravi-
juhist pea pooltele uuringus osalenud meestele ning veerandile uuringus osale-
nud naistele statiinide manustamist südameveresoonkonna haiguste riski vähen-
damiseks, mis näitab, et südameveresoonkonna riskitegurite tasemed on Eesti
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